Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies

被引：30

作者：

Cummings, JL

Zhong, K

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA

[2] MediChamp, Newton, MA 02462 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 01期

关键词：

D O I：

10.1038/nrd1928

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Neuropsychiatric symptoms and behavioural alterations are common in neurodegenerative diseases, and effective treatment of these changes represents an important unmet public health need. Imaging, neuropathological, neurotransmitter and molecular genetic studies increasingly identify specific mechanisms that mediate behavioural changes in neurodegenerative disorders and provide a platform for seeking effective therapeutic interventions. Measuring behavioural outcomes in clinical trials of antidementia agents represents an important means of evaluating treatment effectiveness, and clinical trial methodologies and behavioural instrumentation are evolving to facilitate drug development in this important therapeutic target area.

引用

收藏

页码：64 / 74

页数：11

相关论文

共 129 条

[71] Treating depression in Alzheimer disease - Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS [J].

Lyketsos, CG ;

DelCampo, L ;

Steinberg, M ;

Miles, Q ;

Steele, CD ;

Munro, C ;

Baker, AS ;

Sheppard, JME ;

Frangakis, C ;

Brandt, J ;

Rabins, PV .

ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (07) :737-746

[72] Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus [J].

Malberg, JE ;

Eisch, AJ ;

Nestler, EJ ;

Duman, RS .

JOURNAL OF NEUROSCIENCE, 2000, 20 (24) :9104-9110

[73] Dopaminergic loss and inclusion body formation in α-synuclein mice:: Implications for neurodegenerative disorders [J].

Masliah, E ;

Rockenstein, E ;

Veinbergs, I ;

Mallory, M ;

Hashimoto, M ;

Takeda, A ;

Sagara, Y ;

Sisk, A ;

Mucke, L .

SCIENCE, 2000, 287 (5456) :1265-1269

[74] Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study [J].

McKeith, I ;

Del Ser, T ;

Spano, P ;

Emre, M ;

Wesnes, K ;

Anand, R ;

Cicin-Sain, A ;

Ferrara, R ;

Spiegel, R .

LANCET, 2000, 356 (9247) :2031-2036

[75] Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop [J].

McKeith, IG ;

Galasko, D ;

Kosaka, K ;

Perry, EK ;

Dickson, DW ;

Hansen, LA ;

Salmon, DP ;

Lowe, J ;

MIrra, SS ;

Byrne, EJ ;

Lennox, G ;

Quinn, NP ;

Edwardson, JA ;

Ince, PG ;

Bergeron, C ;

Burns, A ;

Miller, BL ;

Lovestone, S ;

Collerton, D ;

Jansen, ENH ;

Ballard, C ;

deVos, RAI ;

Wilcock, GK ;

Jellinger, KA ;

Perry, RH .

NEUROLOGY, 1996, 47 (05) :1113-1124

[76] Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia [J].

Meehan, KM ;

Wang, HE ;

David, SR ;

Nisivoccia, JR ;

Jones, B ;

Beasley, CM ;

Feldman, PD ;

Mintzer, JE ;

Beckett, LM ;

Breier, A .

NEUROPSYCHOPHARMACOLOGY, 2002, 26 (04) :494-504

[77] The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease [J].

Mega, MS ;

Masterman, DM ;

O'Connor, SM ;

Barclay, TR ;

Cummings, JL .

ARCHIVES OF NEUROLOGY, 1999, 56 (11) :1388-1393

[78] Metabolic patterns associated with the clinical response to galantamine therapy - A fludeoxyglucose F 18 positron emission tomographic study [J].

Mega, MS ;

Dinov, ID ;

Porter, V ;

Chow, G ;

Reback, E ;

Davoodi, P ;

O'Connor, SM ;

Carter, MF ;

Amezcua, H ;

Cummings, JL .

ARCHIVES OF NEUROLOGY, 2005, 62 (05) :721-728

[79] Cerebral correlates of psychotic symptoms in Alzheimer's disease [J].

Mega, MS ;

Lee, L ;

Dinov, ID ;

Mishkin, F ;

Toga, AW ;

Cummings, JL .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (02) :167-171

[80] The spectrum of behavioral changes in Alzheimer's disease [J].

Mega, MS ;

Cummings, JL ;

Fiorello, T ;

Gornbein, J .

NEUROLOGY, 1996, 46 (01) :130-135

← 3 4 5 6 7 8 9 10 11 12 →